NCT04969991View on ClinicalTrials.gov

Study of Varespladib in Patients Hospitalized With Severe COVID-19

PHASE2TerminatedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 30, 2021

Primary Completion Date

February 11, 2022

Study Completion Date

November 22, 2022

Conditions
Coronavirus Disease 2019Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2
Interventions
DRUG

Varespladib

250 mg immediate-release oblong, white, film-coated tablet for oral administration

DRUG

Placebo

Oral formulation matched to the oral varespladib tablet

Trial Locations (7)

33136

University of Miami Miller School of Medicine, Miami

33155

Westchester Research Center at Westchester General Hospital, Miami

46321

Franciscan Alliance, Munster

74104

Ascension St. John Clinical Research Institute, Tulsa

93003

Ventura Clinical Trials, Ventura

02115

The Brigham and Women's Hospital Emergency Medicine, Boston

08103

Cooper University Hospital, Camden

Sponsors

Lead Sponsor

Ophirex, Inc.
All Listed Sponsors
collaborator

Premier Research Group plc

UNKNOWN

lead

Ophirex, Inc.

INDUSTRY